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Sunil V. Rao, MDSEE PAGE 2860F ew therapies in contemporary medicine havebeen as transformative as transcatheter aorticvalve replacement (TAVR). Not only does the
procedure reduce mortality compared with medical
therapy in patients who are not operative candidates
(1), but it is also superior to surgery in high-risk patients
(2). The primary endpoint for the pivotal trials of TAVR
(1,2) has been all-cause mortality, but other events
reﬂecting the safety of the procedure, such as vascular
complications and bleeding, have also been assessed.
As with other endovascular procedures, these events
after TAVR are associated with a signiﬁcant increase
in adverse outcomes such as renal failure andmortality
(3). The early iterations of TAVR devices used very
large bore sheaths (up to 24 F), which likely inﬂuenced
the risk of bleeding and vascular complications in the
elderly and frail patients included in the trials. More-
over, the anticoagulant agent used in the procedures
was 7,000 to 10,000 units of unfractionated heparin
(UFH). In this context, hemorrhagic complications in
the pivotal TAVR trials occurred with a relatively high
frequency. Strategies to mitigate the risk of these com-
plications are a priority in the TAVR space.
Currently available lower proﬁle aortic valve de-
livery sheaths reduce arterial trauma and likely lower
the incidence of bleeding. Another approach, how-
ever, is to manage procedural antithrombotic therapy
in a way that makes the procedure safer. An obvious
choice in this regard is bivalirudin, a direct thrombin
inhibitor with a short half-life, which has been asso-
ciated with reduced bleeding complications in certain*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Duke Clinical Research Institute, Durham, North Carolina. Dr.
Rao has served as a consultant for Medtronic, Terumo Interventional
Systems, and The Medicines Company. Deepak Bhatt, MD, MPH, served
as Guest Editor for this paper.clinical situations. In this issue of the Journal, Dangas
et al. (4) present the results of the BRAVO-3 (Effect of
bivalirudin on Aortic Valve Intervention Outcomes 3)
trial that explores the role of bivalirudin in TAVR. The
trial randomized 802 patients undergoing TAVR to
receive either bivalirudin or UFH. Somewhat sur-
prisingly, the primary endpoints of bleeding at 48 h
post-procedure and net adverse clinical events at 30
days were not signiﬁcantly different between the 2
arms. These results raise several important issues
about approaches to reduce bleeding complications in
a procedural arena that is rapidly evolving.In general, the goals of antithrombin therapy in
cardiovascular procedures are to reduce the risk for
ischemic events and to reduce the risk for thrombus
formation on intravascular equipment. From a clin-
ical standpoint, optimal anticoagulation therapy
should meet these goals while not increasing the risk
of bleeding. Although several agents have been
studied for use during percutaneous coronary inter-
vention (PCI), UFH and bivalirudin are the most
commonly used. UFH is the traditional choice; it is
inexpensive, titrable, and reversible. However,
UFH also has several well-known limitations, such as
unpredictable levels of anticoagulation, platelet
activation, and potential for heparin-induced throm-
bocytopenia. Bivalirudin overcomes many of these
limitations, and its short half-life allows for a rapid
offset, theoretically reducing bleeding risk post-
procedure. Some randomized trials have supported
this putative beneﬁt, particularly when bivalirudin
was compared against a combination of UFH and a
glycoprotein IIb/IIIa inhibitor (GPI) (5). Later trials
have not been as deﬁnitive. A pooled analysis of 16
randomized trials, including >33,000 patients un-
dergoing PCI, found that bivalirudin does signiﬁ-
cantly reduce bleeding compared with a strategy of
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GPI added to bivalirudin, this safety advantage is no
longer present (6). What accounts for these differ-
ences, and how does it relate to procedural strategies
for TAVR?
It is important to recognize that procedural medi-
cine rarely stagnates. Devices and techniques
continue to iterate, and adjuvant medical therapy
also evolves, often rapidly. An example of this evo-
lution is the adoption of a radial approach to PCI. Both
randomized and observational data deﬁnitively indi-
cate that using radial access signiﬁcantly reduces
bleeding risk compared with femoral access (7). In
high-risk patients such as those with ST-segment
elevation myocardial infarction undergoing primary
PCI, the radial approach is also associated with a
reduction in mortality (8). Because the majority of
bleeding complications after PCI are access site
related, the value of an antithrombotic strategy aimed
at reducing bleeding may have less relevance in the
setting of transradial PCI. Of course, nonaccess site
bleeding (e.g., gastrointestinal hemorrhage) may also
be an issue, but these bleeding events are likely more
closely related to prolonged post-procedure infusions
of GPI rather than the antithrombin therapy itself.
With the advent of more potent oral antiplatelet
agents, the use of GPI has dramatically decreased
over time. Therefore, contemporary PCI involves
radial access, low-proﬁle arterial access introducer
sheaths (5- or 6-F), loading of oral antiplatelet agents,
and selective use of GPI, all of which reduce ischemic
and bleeding complications. A trial speciﬁcally
testing this strategy in patients with ST-segment
elevation myocardial infarction demonstrated no
beneﬁt of bivalirudin on major adverse cardiovascu-
lar events or on bleeding outcomes (9).
The pivotal trials of TAVR demonstrated 30-day
major vascular complication rates of 5.9% to 17.0%
and major bleeding rates of 9.3% to 28.0% with
transcatheter procedures. These rates are several-fold
higher than any seen in studies of PCI. If bivalirudin
does positively affect bleeding outcomes, TAVR is the
ideal setting in which that should be evident, but the
results of the BRAVO-3 trial suggest otherwise (4).
There are 3 potential reasons for this lack of effect: 1)
bivalirudin is not effective at reducing bleeding
complications; 2) other factors inﬂuence bleeding and
negate the effect of bivalirudin; and 3) the trial is
subject to type II error and was not adequately pow-
ered. The data from the published reports of PCI
summarized earlier indicate that bivalirudin may be
safer than UFH but only in the setting of a femoral
approach and when UFH is used in combination with
GPI. Thus, the issue of whether bivalirudin trulyreduces bleeding risk is highly dependent on other
procedural factors. For example, in the BRAVO-3 trial,
the majority of patients in both groups underwent the
procedure using an introducer sheath size of #18-F
(smaller than those used in the earlier TAVR trials),
which likely lowered the overall risk for bleeding.
Moreover, >90% of patients had the femoral arterio-
tomy successfully closed with a closure device. With
respect to antithrombin dosing, which is critical to
reducing bleeding risk (10), the trial recommended
titration of UFH dosing to achieve an activated clot-
ting time (ACT) of 250 s. Although the ACT values are
not reported, the overall rate of bleeding complica-
tions was lower than those reported in the pivotal
trials of TAVR, suggesting that sheath size, method of
hemostasis, and UFH dosing all negated the effect of
bivalirudin. The lower rate of bleeding also subjects
the trial to type II error. The sample size of BRAVO-3
was based on an assumed major bleeding rate of 19%
in the control (UFH) group and a 47% relative risk
reduction with bivalirudin. The actual rate of
bleeding complications in the UFH arm was 9.0%,
much less than what was expected. With this event
rate, the trial would have needed at least 1,700 pa-
tients (i.e., more than double the number actually
enrolled) to have 80% power to show a 40% reduction
in bleeding complications with bivalirudin. It thus
seems that all 3 elements may have inﬂuenced the
results of BRAVO-3.
These negative results call into question the role of
bivalirudin in TAVR. Because the BRAVO-3 trial
showed that bivalirudin was noninferior to UFH with
respect to 30-day net adverse cardiovascular events
(a composite of all-cause mortality, myocardial
infarction, or stroke; and major bleeding) and the
rates of all endpoints were numerically lower in the
bivalirudin-treated group (4), bivalirudin seems to be
a reasonable alternative to UFH for TAVR. However,
the cost difference between the 2 agents begs the
question of when bivalirudin should be considered.
An obvious situation is when the patient has heparin-
induced thrombocytopenia. Another clinical scenario
in which bivalirudin can be considered is when very
large doses or repeated doses of UFH may be neces-
sary to maintain therapeutic ACT values, such as in
patients who are overweight or obese. The predict-
able anticoagulant effect of bivalirudin could provide
an advantage in this context. Other than these spe-
ciﬁc conditions, there is no question that until further
data are available, UFH is the preferred agent for
TAVR.
The ﬁndings of the BRAVO-3 trial (4) are an
important reminder that cardiovascular procedures
are multifaceted, comprising devices, techniques,
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2871and adjuvant medical therapy. All 3 dimensions can
evolve and often do, with a change in 1 affecting the
others. A constant re-evaluation of each is necessary
to determine the optimal combination to balance ef-
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